Welcome to our dedicated page for Nanovibronix SEC filings (Ticker: NAOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings historically submitted under the ticker NAOV for NanoVibronix, Inc., which subsequently changed its name to ENvue Medical, Inc. and its Nasdaq symbol to FEED. These documents provide a regulatory record of the company’s activities as a medical technology issuer focused on non-invasive therapeutic systems and minimally invasive navigation platforms.
Among the filings accessible here are Form 8-K current reports describing material events such as the corporate name change to ENvue Medical, Inc. and the symbol change from NAOV to FEED, the implementation of a 1-for-10 reverse stock split of common stock, and various financing transactions involving registered direct offerings, pre-funded warrants, and Series H Convertible Preferred Stock with associated warrants. Other 8-K filings discuss board and executive changes, special and annual meeting matters, and significant agreements.
The archive also includes a DEF 14A definitive proxy statement outlining proposals presented at the 2025 annual meeting of stockholders, including director elections, auditor ratification, amendments to equity incentive plans, and approvals required under Nasdaq Listing Rule 5635(d) for certain equity issuances. A Form 12b-25 (NT 10-Q) notification of late filing is available, explaining the need for additional time to complete a quarterly report for the period ended June 30, 2025.
On Stock Titan, these filings are presented with AI-powered tools that can help explain the structure and implications of documents such as 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements, and registration-related filings. Users can also review disclosures related to capital structure changes, preferred stock designations, warrant terms, and other corporate actions that shaped the company’s transition from NanoVibronix, Inc. (NAOV) to ENvue Medical, Inc. (FEED). For ongoing filings after the name and ticker change, investors should refer to submissions under the FEED symbol.
ENvue Medical, Inc. is registering the resale of up to 7,962,279 shares of common stock for a selling stockholder. These include 2,377,533 shares issuable upon conversion of Series H Convertible Preferred Stock, 584,796 shares issuable upon exercise of related warrants, and up to 4,999,950 shares issuable as stock dividends on the Series H shares at a 9% annual rate. The company will not receive proceeds from any resale, but may receive cash if the warrants are exercised, which it plans to use for general corporate purposes. As of December 5, 2025, 1,088,192 common shares were outstanding, so full issuance of the registered shares would represent a very large increase in the share count and substantial dilution for existing holders. The filing also notes the company’s reverse stock splits, recent merger, name and ticker change to “FEED,” and ongoing Nasdaq listing compliance and auditor-related risks.
ENvue Medical, Inc., formerly known as NanoVibronix, Inc., has amended its certificate of incorporation to change its corporate name to ENvue Medical, Inc., effective December 12, 2025. On the same date, its common stock stopped trading on Nasdaq under the ticker symbol “NAOV” and began trading under the new symbol “FEED.”
The company states that the name change and ticker change do not affect the rights of its security holders and that its CUSIP remains the same. Under Delaware law, this amendment did not require stockholder approval. The company also issued a press release on December 12, 2025 to announce the name and symbol changes.
NanoVibronix, Inc. (NAOV) filed a current report announcing that it issued a shareholder letter on November 19, 2025. The letter was provided to investors as an exhibit to this report under a disclosure rule that covers company communications with the market, rather than as a formal financial or earnings filing. The report clarifies that this communication is being furnished, not filed, which means it is not automatically incorporated into other securities law filings or subject to certain legal liabilities.
NanoVibronix, Inc. filed its definitive proxy for the 2025 Annual Meeting. The virtual meeting is set for December 4, 2025, at 10:00 a.m. ET via www.virtualshareholdermeeting.com/NAOV2025. Stockholders of record as of October 27, 2025 may vote.
The ballot includes: electing five directors (Doron Besser, M.D.; Zeev Rotstein, M.D.; David Johnson; Nino Pionati; and Alison Geiger Burgett), ratifying E&Y (Kost Forer Gabbay & Kasierer) as auditor, amending the 2024 Long‑Term Incentive Plan to increase authorized shares under the plan, authorizing—solely for Nasdaq Listing Rule 5635(d) compliance—the issuance of common shares underlying July 2025 convertible preferred stock and warrants in an amount equal to or in excess of 19.99% of pre‑transaction common stock, and an adjournment proposal if needed.
Common stock outstanding was 1,011,102 shares on the record date. Series G (820 shares), Series H (11,111 shares) and Series X (53,100 shares) preferred are outstanding but not entitled to vote at the meeting.
NanoVibronix, Inc. (NAOV) filed a preliminary proxy for its 2025 Annual Meeting to be held virtually on December 4, 2025 at 10:00 a.m. ET at www.virtualshareholdermeeting.com/NAOV2025. Stockholders of record as of October 27, 2025 may vote.
The agenda includes: electing five directors (Doron Besser, M.D.; Zeev Rotstein, M.D.; David Johnson; Nino Pionati; Alison Geiger Burgett); ratifying E&Y as auditor; amending the 2024 Long‑Term Incentive Plan to increase authorized shares; an Issuance Proposal to authorize, for Nasdaq Rule 5635(d), the issuance of common shares underlying July 2025 convertible preferred stock and warrants in an amount equal to or in excess of 19.99% of pre‑issuance common outstanding (including anti‑dilution adjustments); and an adjournment proposal.
Holders had 1,011,102 shares of common stock outstanding as of the Record Date. The Board recommends voting FOR all proposals.
NanoVibronix (NAOV) reported board changes under Item 5.02. On October 30, 2025, Christopher Fashek, Thomas Mika, Martin Goldstein, M.D., and Brian Murphy notified the Board that they will not stand for reelection and will retire from the Board and all committees, effective immediately prior to the 2025 Annual Meeting of Stockholders.
The filing notes their decisions were for personal reasons and did not result from any disagreement regarding the company’s operations, policies, or practices. As of the notice date, Mr. Fashek served on the Audit, Nominating and Corporate Governance, and Compensation Committees; Mr. Mika served on the Audit and Compensation Committees; and Dr. Goldstein served on the Nominating and Corporate Governance Committee.
NanoVibronix, Inc. amended its shelf registration showing that its Series H Shares are convertible at the election of holders into common stock at an adjusted conversion price of
NanoVibronix, Inc. entered into a securities purchase agreement with a single institutional investor for a registered direct offering of equity. The company agreed to sell 74,114 shares of common stock and prefunded warrants to purchase up to 217,090 additional shares, all under an effective shelf registration. The offering price was $7.01 per share of common stock and $7.009 per prefunded warrant, reflecting a $0.001 exercise price per warrant share. NanoVibronix reports net proceeds of about $1.8 million after fees, which it currently plans to use mainly for general working capital, including repayment of certain debt and/or redemption of preferred stock. The prefunded warrants have a very low exercise price and may be exercised until fully used, subject to a 4.99% (or, at the holder’s election, 9.99%) beneficial ownership cap that can be adjusted with 61 days’ prior notice.
NanoVibronix, Inc. (NAOV) filed a prospectus supplement for an offering that includes prefunded warrants and common stock, showing an offering price of $0.56 per unit and placement agent fees of $0.56 per unit. The document reports proceeds before expenses of $1,877,815.75 and placement agent fees totaling $163,307.20. It discloses shares issuable upon exercise of outstanding warrants: 1,151,695 shares at a weighted average exercise price of $22.81 and 683,859 shares at a weighted average exercise price of $23.03. Historical net tangible book value per share as of June 30, 2025 is $(4.66); pro forma adjustments add $3.81, yielding a pro forma as-adjusted net tangible book value of $(0.85) and an increase attributable to this offering of $1.90. The filing references standard prospectus sections including risk factors and use of proceeds and notes uncertainty regarding clinical trial success for products in development.